| Title |
Practical management of patients on apixaban: a consensus guide
|
|---|---|
| Published in |
Thrombosis Journal, December 2013
|
| DOI | 10.1186/1477-9560-11-27 |
| Pubmed ID | |
| Authors |
Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus, Simon McRae |
| Abstract |
Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mortality and morbidity. Stroke prevention is therefore a key management strategy for AF patients, in addition to rate and rhythm control. Anticoagulation with warfarin has been an enduring gold standard for stroke prevention in NVAF patients. In Australia, three novel oral anticoagulants (NOACs), apixaban, dabigatran and rivaroxaban are now approved and reimbursed for stroke prevention in patients with non-valvular AF (NVAF). International European Cardiology guidelines now recommend either a NOAC or warfarin for NVAF patients with a CHA2DS2-VASc score ≥2, unless contraindicated. Apixaban is a direct factor Xa inhibitor with a 12-hour half-life and 25% renal excretion that was found in a large trial of NVAF patients to be superior to warfarin in preventing stroke or systemic embolism. In this trial population, apixaban also resulted in less bleeding and a lower mortality rate than warfarin. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Kuwait | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Slovenia | 1 | <1% |
| Unknown | 121 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 27 | 22% |
| Other | 22 | 18% |
| Student > Bachelor | 17 | 14% |
| Researcher | 12 | 10% |
| Professor > Associate Professor | 8 | 7% |
| Other | 18 | 15% |
| Unknown | 19 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 59 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 15% |
| Nursing and Health Professions | 6 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Other | 9 | 7% |
| Unknown | 22 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2014.
All research outputs
#20,655,488
of 25,373,627 outputs
Outputs from Thrombosis Journal
#330
of 406 outputs
Outputs of similar age
#242,866
of 318,820 outputs
Outputs of similar age from Thrombosis Journal
#3
of 4 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 406 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,820 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.